vs
ANI PHARMACEUTICALS INC（ANIP）とCSG SYSTEMS INTERNATIONAL INC（CSGS）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSG SYSTEMS INTERNATIONAL INCの直近四半期売上が大きい（$323.1M vs $247.1M、ANI PHARMACEUTICALS INCの約1.3倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 2.2%、差は9.0%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 2.0%）。CSG SYSTEMS INTERNATIONAL INCの直近四半期フリーキャッシュフローが多い（$55.8M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 4.6%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
中国南玻集団股フン有限公司は中国最大級の建築用ガラスメーカーで、浮きガラス、建築用ガラス、ディスプレイ用ガラス、自動車用ガラス、コーティングガラス、鏡、カラーフィルターガラス、太陽光発電用ガラス、省エネガラスなど多種多様なガラス製品の製造・販売を手がけています。
ANIP vs CSGS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $323.1M |
| 純利益 | $27.5M | $7.0M |
| 粗利率 | — | 50.0% |
| 営業利益率 | 14.1% | 9.0% |
| 純利益率 | 11.1% | 2.2% |
| 売上前年比 | 29.6% | 2.0% |
| 純利益前年比 | 367.5% | -79.7% |
| EPS（希薄化後） | $1.14 | $0.24 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $323.1M | ||
| Q3 25 | $227.8M | $303.6M | ||
| Q2 25 | $211.4M | $297.1M | ||
| Q1 25 | $197.1M | $299.5M | ||
| Q4 24 | $190.6M | $316.7M | ||
| Q3 24 | $148.3M | $295.1M | ||
| Q2 24 | $138.0M | $290.3M | ||
| Q1 24 | $137.4M | $295.1M |
| Q4 25 | $27.5M | $7.0M | ||
| Q3 25 | $26.6M | $20.5M | ||
| Q2 25 | $8.5M | $12.3M | ||
| Q1 25 | $15.7M | $16.1M | ||
| Q4 24 | $-10.3M | $34.5M | ||
| Q3 24 | $-24.2M | $19.1M | ||
| Q2 24 | $-2.3M | $13.8M | ||
| Q1 24 | $18.2M | $19.5M |
| Q4 25 | — | 50.0% | ||
| Q3 25 | — | 48.1% | ||
| Q2 25 | — | 49.5% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | 51.3% | ||
| Q3 24 | — | 49.4% | ||
| Q2 24 | — | 47.3% | ||
| Q1 24 | — | 46.5% |
| Q4 25 | 14.1% | 9.0% | ||
| Q3 25 | 15.9% | 10.0% | ||
| Q2 25 | 6.6% | 10.0% | ||
| Q1 25 | 13.3% | 9.8% | ||
| Q4 24 | -2.3% | 13.4% | ||
| Q3 24 | -13.8% | 10.8% | ||
| Q2 24 | 3.7% | 8.8% | ||
| Q1 24 | 14.8% | 10.8% |
| Q4 25 | 11.1% | 2.2% | ||
| Q3 25 | 11.7% | 6.7% | ||
| Q2 25 | 4.0% | 4.1% | ||
| Q1 25 | 8.0% | 5.4% | ||
| Q4 24 | -5.4% | 10.9% | ||
| Q3 24 | -16.3% | 6.5% | ||
| Q2 24 | -1.7% | 4.8% | ||
| Q1 24 | 13.2% | 6.6% |
| Q4 25 | $1.14 | $0.24 | ||
| Q3 25 | $1.13 | $0.73 | ||
| Q2 25 | $0.36 | $0.44 | ||
| Q1 25 | $0.69 | $0.57 | ||
| Q4 24 | $-0.45 | $1.20 | ||
| Q3 24 | $-1.27 | $0.67 | ||
| Q2 24 | $-0.14 | $0.48 | ||
| Q1 24 | $0.82 | $0.68 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $180.0M |
| 総負債低いほど良い | — | $539.5M |
| 株主資本純資産 | $540.7M | $283.7M |
| 総資産 | $1.4B | $1.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 1.90× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $180.0M | ||
| Q3 25 | $262.6M | $158.4M | ||
| Q2 25 | $217.8M | $145.9M | ||
| Q1 25 | $149.8M | $136.0M | ||
| Q4 24 | $144.9M | $161.8M | ||
| Q3 24 | $145.0M | $118.4M | ||
| Q2 24 | $240.1M | $110.4M | ||
| Q1 24 | $228.6M | $120.8M |
| Q4 25 | — | $539.5M | ||
| Q3 25 | — | $538.6M | ||
| Q2 25 | — | $537.8M | ||
| Q1 25 | — | $537.6M | ||
| Q4 24 | — | $538.5M | ||
| Q3 24 | — | $539.5M | ||
| Q2 24 | — | $540.5M | ||
| Q1 24 | — | $541.5M |
| Q4 25 | $540.7M | $283.7M | ||
| Q3 25 | $505.8M | $289.5M | ||
| Q2 25 | $436.8M | $290.7M | ||
| Q1 25 | $418.6M | $283.1M | ||
| Q4 24 | $403.7M | $282.6M | ||
| Q3 24 | $405.9M | $288.4M | ||
| Q2 24 | $455.8M | $273.3M | ||
| Q1 24 | $452.0M | $269.3M |
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $920.8M | $1.4B | ||
| Q1 24 | $914.5M | $1.3B |
| Q4 25 | — | 1.90× | ||
| Q3 25 | — | 1.86× | ||
| Q2 25 | — | 1.85× | ||
| Q1 25 | — | 1.90× | ||
| Q4 24 | — | 1.91× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | — | 2.01× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $59.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $55.8M |
| FCFマージンFCF / 売上 | 11.8% | 17.3% |
| 設備投資強度設備投資 / 売上 | 0.5% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 8.46× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $141.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $59.2M | ||
| Q3 25 | $44.1M | $47.9M | ||
| Q2 25 | $75.8M | $37.3M | ||
| Q1 25 | $35.0M | $11.5M | ||
| Q4 24 | $15.9M | $82.5M | ||
| Q3 24 | $12.5M | $39.5M | ||
| Q2 24 | $17.4M | $43.1M | ||
| Q1 24 | $18.3M | $-29.4M |
| Q4 25 | $29.1M | $55.8M | ||
| Q3 25 | $38.0M | $43.9M | ||
| Q2 25 | $71.8M | $34.6M | ||
| Q1 25 | $32.5M | $7.1M | ||
| Q4 24 | $13.5M | $76.6M | ||
| Q3 24 | $7.7M | $32.0M | ||
| Q2 24 | $13.0M | $38.8M | ||
| Q1 24 | $13.7M | $-34.1M |
| Q4 25 | 11.8% | 17.3% | ||
| Q3 25 | 16.7% | 14.5% | ||
| Q2 25 | 34.0% | 11.6% | ||
| Q1 25 | 16.5% | 2.4% | ||
| Q4 24 | 7.1% | 24.2% | ||
| Q3 24 | 5.2% | 10.8% | ||
| Q2 24 | 9.4% | 13.4% | ||
| Q1 24 | 10.0% | -11.6% |
| Q4 25 | 0.5% | 1.1% | ||
| Q3 25 | 2.7% | 1.3% | ||
| Q2 25 | 1.9% | 0.9% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 1.3% | 1.9% | ||
| Q3 24 | 3.2% | 2.5% | ||
| Q2 24 | 3.2% | 1.5% | ||
| Q1 24 | 3.3% | 1.6% |
| Q4 25 | 1.10× | 8.46× | ||
| Q3 25 | 1.66× | 2.34× | ||
| Q2 25 | 8.87× | 3.04× | ||
| Q1 25 | 2.23× | 0.71× | ||
| Q4 24 | — | 2.39× | ||
| Q3 24 | — | 2.07× | ||
| Q2 24 | — | 3.12× | ||
| Q1 24 | 1.00× | -1.51× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
